nach oben

Wiener Medizinische Wochenschrift

Erschienen in:

01.12.2014 | review

Pressurized intraperitoneal chemotherapy (PIPAC) in women with gynecologic malignancies: a review

verfasst von: Prof. Clemens B. Tempfer, MD, MBA, Wiebke Solass, MD, Prof. Marc-André Reymond, MD

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 23-24/2014

Einloggen, um Zugang zu erhalten

Summary

Objective

The objective of this study was to provide an overview of published and ongoing trials of pressurized intraperitoneal chemotherapy (PIPAC) in ovarian cancer.

Design

The study comprised a systematic literature review.

Results

We identified 10 studies, including 2 ex vivo and in vitro studies, 6 clinical studies, and 2 ongoing clinical trials using PIPAC in women with recurrent ovarian cancer and pseudomyxoma peritonei. Experimental evidence and clinical study data demonstrate that PIPAC increases peritoneal cavity coverage and depth of peritoneal infiltration, and is technically feasible. Occupational safety has been established. PIPAC has demonstrated antitumor activity based on histological, radiological, and clinical evidence. The toxicity of PIPAC is manageable and restricted to Common Terminology Criteria for Adverse Events grade 2–3 events when used without concomitant cytoreductive surgery. Further clinical trials assessing efficacy and dose escalation are ongoing.

Conclusions

PIPAC is technically feasible, has a safe local and systemic safety profile, and has antitumor activity in women with peritoneal carcinomatosis from recurrent ovarian cancer.

Vorheriger Artikel Renal denervation in the treatment of resistant arterial hypertension

Nächster Artikel Relapsing advanced metatypical basal cell carcinomas (MTBCC) of the face: Surgical modalities

Foley OW, Rauh-Hain JA, del Carmen MG. Recurrent epithelial ovarian cancer: an update on treatment. Oncology. 2013;27(4):288–94.PubMed

Hanker LC, Loibl S, Burchardi N, Pfisterer J, Meier W, Pujade-Lauraine E, Ray-Coquard I, Sehouli J, Harter P, du Bois A, AGO and GINECO study group. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. Ann Oncol. 2012;23(10):2605–12.PubMedCrossRef

Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA, Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34–43.PubMedCrossRef

Gadducci A, Conte PF. Intraperitoneal chemotherapy in the management of patients with advanced epithelial ovarian cancer: a critical review of the literature. Int J Gynecol Cancer. 2008;18(5):943–53.PubMedCrossRef

Varona JF, Guerra JM, Salamanca J, Colina F, Lopez G, Morales M. Pseudomyxoma peritonei: a clinicopathologic analysis and follow-up of 21 patients. Hepatogastroenterology. 2005;52(63):812–6.PubMed

McBride K, McFadden D, Osler T. Improved survival of patients with pseudomyxoma peritonei receiving intraperitoneal chemotherapy with cytoreductive surgery: a systematic review and meta-analysis. J Surg Res. 2013;183(1):246–52.PubMedCrossRef

Saxena A, Yan TD, Chua TC, Morris DL. Critical assessment of risk factors for complications after cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol. 2010;17(5):1291–301.PubMedCrossRef

Eskander RN, Tewari KS. Emerging treatment options for management of malignant ascites in patients with ovarian cancer. Int J Womens Health. 2012;4:395–404.PubMedCentralPubMed

Dedrick RL, Flessner MF. Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure. J Natl Cancer Inst. 1997;89:480–7.PubMedCrossRef

10.

Esquis P, Consolo D, Magnin G, Pointaire P, Moretto P, Ynsa MD, Beltramo JL, Drogoul C, Simonet M, Benoit L, Rat P, Chauffert B. High intra-abdominal pressure enhances the penetration and antitumor effect of intraperitoneal cisplatin on experimental peritoneal carcinomatosis. Ann Surg. 2006;244(1):106–12.PubMedCentralPubMedCrossRef

11.

Solass W, Herbette A, Schwarz T, Hetzel A, Sun JS, Dutreix M, Reymond MA. Therapeutic approach of human peritoneal carcinomatosis with Dbait in combination with capnoperitoneum: proof of concept. Surg Endosc. 2012;26(3):847–52.PubMedCentralPubMedCrossRef

12.

Solass W, Hetzel A, Nadiradze G, Sagynaliev E, Reymond MA. Intraoperative intraperitonal drug delivery using a nebulizer: rationale and pharmacokinetic results. Surg Endosc. 2012;26(7):1849–55.PubMedCrossRef

13.

Solass W, Kerb R, Muerdter T, Giger U, Strumberg D, Tempfer C, Zieren J, Schwab M. Reymond. intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy. Ann Surg Oncol. 2014;21(2):553–9.PubMedCentralPubMedCrossRef

14.

Solass W, Giger-Pabst U, Zieren J, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy (PIPAC): occupational health and safety aspects. Ann Surg Oncol. 2013;20(11):3504–11.PubMedCentralPubMedCrossRef

15.

Blanco A, Giger-Pabst U, Solass W, Zieren J, Reymond MA. Renal and hepatic toxicities after pressurized intraperitoneal aerosol chemotherapy (PIPAC). Ann Surg Oncol. 2013;20(7):2311–6.PubMedCentralPubMedCrossRef

16.

Tempfer CB, Celik I, Solass W, Buerkle B, Pabst UG, Zieren J, Strumberg D, Reymond MA. Activity of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with cisplatin and doxorubicin in women with recurrent, platinum-resistant ovarian cancer: preliminary clinical experience. Gynecol Oncol. 2014;132(2):307–11.PubMedCrossRef

17.

Tempfer C, Solass W, Buerkle B, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin in a woman with pseudomyxoma peritonei. Int J Gynecol Cancer, submitted (2014).

18.

Giger-Pabst U, Solass W, Buerkle B, Reymond MA, Tempfer C. Low-dose pressurized intraperitoneal aerosol chemotherapy (PIPAC) as an alternative therapy for ovarian cancer in an octogenarian patient. Gynecol Oncol Case Reports, submitted (2014).

19.

https://clinicaltrials.gov/ct2/show/NCT01809379?term=PIPAC&rank=2. Accessed 13 Juli 2014.

20.

https://eudract.ema.europa.eu/document.html. Accessed 13 Juli 2014.

21.

Mazzei MA, Khader L, Cirigliano A, Cioffi Squitieri N, Guerrini S, Forzoni B, Marrelli D, Roviello F, Mazzei FG, Volterrani L. Accuracy of MDCT in the preoperative definition of Peritoneal Cancer Index (PCI) in patients with advanced ovarian cancer who underwent peritonectomy and hyperthermic intraperitoneal chemotherapy (HIPEC). Abdom Imaging. 2013;38(6):1422–30.PubMedCrossRef

22.

Common Terminology Criteria for Adverse Events (CTCAE) version 4.0; published: May 28, 2009 (v4.03: June 14, 2010); U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute.

23.

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.PubMedCrossRef

Titel: Pressurized intraperitoneal chemotherapy (PIPAC) in women with gynecologic malignancies: a review
verfasst von: Prof. Clemens B. Tempfer, MD, MBA
Wiebke Solass, MD
Prof. Marc-André Reymond, MD
Publikationsdatum: 01.12.2014
Verlag: Springer Vienna
Erschienen in: Wiener Medizinische Wochenschrift / Ausgabe 23-24/2014
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI: https://doi.org/10.1007/s10354-014-0312-y

Springer Medizin Österreich

Summary

Objective

Design

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 23-24/2014

Relapsing advanced metatypical basal cell carcinomas (MTBCC) of the face: Surgical modalities

Carotid interventions and blood pressure

Stellungnahme zu Schwarz E., Maier M. – Publication output in the field of Public Health and its appreciation at political level in Austria, Wien Med Wochenschr (2014) 164:123–130

Stellungnahme zu Schwarz E., Maier M. – Publication output in the field of Public Health and its appreciation at political level in Austria, Wien Med Wochenschr (2014) 164:123–130

Electrical carotid baroreceptor stimulation

Professor Gerhart Hitzenberger zum 85. Geburtstag